Current evidence and therapeutic strategies for multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) management has evolved with numerous immunomodulatory and immunosuppressive therapies.
• Six therapies are currently approved for multiple sclerosis treatment.
• Clinical decision-making is complicated by drug availability and lack of direct efficacy comparisons.

Purpose of the Study:

• To review the current evidence supporting the efficacy of available multiple sclerosis drugs.
• To identify areas where further research is needed.
• To highlight the necessity for novel therapeutic strategies in multiple sclerosis management.

Main Methods:

• Review of existing scientific literature on multiple sclerosis therapies.
• Analysis of clinical trial data and evidence supporting drug efficacy.
• Identification of gaps in current treatment protocols and management algorithms.

Main Results:

• Current multiple sclerosis therapies offer partial effectiveness, leading to breakthrough disease activity in most patients.
• Lack of head-to-head comparisons hinders direct efficacy assessment of available drugs.
• Special factors, like neutralizing antibodies, can influence treatment efficacy.

Conclusions:

• There is a significant need for emerging therapies and advanced management strategies for multiple sclerosis.
• Investigative oral and parenteral agents, alongside combination therapy approaches, are essential for future multiple sclerosis treatment.
• Development of validated treatment failure definitions and management algorithms is critical for optimizing patient care.